Vitamin B12: a Biological Marker of Systemic Disease or Infection Flare-up in Patients Treated with Tocilizumab?

NARecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2029

Conditions
Level of Serum Vitamin B12 Level (in Pmol/L) If Relapse of (AI/ID) Under TocilizumabLevel of Serum Vitamin B12 Level (in Pmol/L) If Infection Under Tocilizumab
Interventions
DIAGNOSTIC_TEST

variation of serum level vitamine B12

"There will be no specific visit to the study. Follow-up in consultation will be done by your referring doctor. A determination of the serum level of vitamin B12 will be carried out at inclusion, during a consultation where the pathology is in remission (during the classic assessment of follow-up under tocilizumab, left to the discretion of the patient's referring doctor. ). It will also be necessary to carry out, in addition to the classic assessment left to the discretion of the patient's doctor, a determination of the serum level of vitamin B12 in the event of clinical suspicion of infection or an outbreak of MAI/I.~The determination of serum vitamin B12 requires the collection of an additional tube of 300 μl of venous blood but no additional venipuncture"

Trial Locations (1)

Unknown

RECRUITING

CHU clermont-ferrand, Clermont-Ferrand

All Listed Sponsors
lead

University Hospital, Clermont-Ferrand

OTHER